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ENGLISH SUMMARY 
Venous thromboembolism is a common vascular disease affecting millions of 
individuals worldwide. Venous thromboembolism covers both deep vein 
thrombosis and pulmonary embolism. One major concern related to venous 
thromboembolism is a long-lasting high risk of recurrence, which is associated with 
high morbidity and mortality.  
Anticoagulation is highly effective for preventing venous thromboembolism 
recurrence but involves a trade-off, since this treatment can also cause severe and 
potentially life-threatening bleeding. The optimal duration of anticoagulation is 
undetermined – in large due to uncertainties about the individual patient’s risk of 
recurrence. International guidelines do not recommend any specific risk 
stratification tool to guide the treatment decision, besides an arbitrary 
categorisation into ‘provoked’, ‘unprovoked’ and ‘cancer-related’ venous 
thromboembolism. Furthermore, despite recommendations of anticoagulant 
treatment to all patients with incident venous thromboembolism, some patients 
never initiate this critical treatment.  
This thesis is based on three register-based studies ultimately striving towards a 
more informed navigation in some of the dilemmas of venous thromboembolism 
treatment. Study 1 aimed at clarifying recurrence risk according to the 
categorization of venous thromboembolism suggested in most guidelines. After 10 
years, the risk of recurrence was approximately 20% among patients with cancer 
and ‘unprovoked’ venous thromboembolism. However, contrary to common 
belief, patients with ‘provoked’ venous thromboembolism also carried a high 
recurrence risk greater than 15% after 10 years. Therefore, in Study 2 we 
abandoned the traditional arbitrary categorization of ‘provoked’ and ‘unprovoked’ 
venous thromboembolism, when we derived and internally validated sex-specific 
risk prediction scores for venous thromboembolism recurrence. We developed a 
well-calibrated risk score under the acronym AIM-SHA-RP, which may be used to 
guide decisions of oral anticoagulant treatment duration following incident VTE. 
Finally, to embolden focus on adherence and optimal treatment, Study 3 
investigated potential predictors of non-initiation of anticoagulation after incident 
venous thromboembolism. Up to 24% did not initiate relevant anticoagulant 
treatment within 30 days after discharge. Most robust predictors of non-initiation 
were demographic and condition-related factors including female sex, young age, 
and incident deep venous thrombosis. 
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This Ph.D. dissertation emphasizes a continued need for improvement of venous 
thromboembolism treatment and management. The thesis clarifies that venous 
thromboembolism recurrence is common, and that many patients receive no or 
potentially sub-optimal anticoagulant treatment. Alongside with other scientific 
contributions, the presented studies may support the decision of anticoagulant 
treatment duration of the many patients suffering from venous 
thromboembolism. 
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DANSK RESUME 
Blodprop i venerne, også kaldet venøs tromboemboli, dækker både over 
blodpropper i de dybe vener (dyb venetrombose) samt blodpropper i 
lungearterierne (lungeemboli). Venøs tromboemboli er en hyppig vaskulær 
sygdom, som hvert år rammer millioner af mennesker på verdensplan. En af 
hovedbekymringerne efter venøs tromboemboli er den høje risiko for 
efterfølgende ny (recidiv) blodprop i venerne. Recidiv af venøs tromboemboli er 
forbundet med både øget sygelighed og høj dødelighed.  
Blodfortyndende medicin er yderst effektiv til at forebygge recidiv af venøs 
tromboemboli, men kan også kan forårsage svær og potentielt livstruende 
blødning. Den optimale varighed af behandling med blodfortyndende medicin er 
uafklaret – primært pga. usikkerhed omkring risikoen for recidiv-risikoen hos den 
enkelte patient. Internationale retningslinjer anbefaler ikke noget specifikt værktøj 
til opdeling af risikogrupper, som en guide for beslutningen af varighed af 
behandling udover en arbitrær opdeling i ”provokeret”, ”uprovokeret” og ”cancer-
relateret” venøs tromboemboli. Til trods for, at blodfortyndende medicin 
anbefales til alle patienter med venøs tromboemboli, er der desuden patienter, 
der aldrig opstarter den relevante behandling. 
Denne afhandling bygger på tre register-baserede studier, der bidrager med ny 
viden til dilemmaet omkring behandling af venøs tromboemboli. Formålet med 
Studie 1 var, at belyse risikoen for recidiv i forhold til den opdeling af venøs 
tromboemboli man ser i de fleste retningslinjer. Patienter med kræft samt 
patienter med uprovokeret venøs tromboemboli havde den højeste recidiv-risiko 
på cirka 20% efter 10 år. Mod forventning havde patienter med provokeret venøs 
tromboemboli også en høj risiko på mere end 15% efter 10 år. Derfor undlod vi 
den traditionelle arbitrære opdeling i ”provokeret” og ”uprovokeret” venøs 
tromboemboli, da vi i Studie 2 udviklede og internt validerede en køns-specifik 
risikoprædiktions-score til recidiv af venøs tromboemboli. Vi udviklede en 
velkalibreret risikoscore under akronymet AIM-SHA-RP. Endelig, med henblik på at 
forbedre compliance og behandling, undersøgte vi i Studie 3 potentielle faktorer, 
som vil kunne forudsige, hvilke patienter, der ikke opstarter blodfortyndende 
behandling efter første venøse tromboemboli. Op mod 24% opstartede ikke 
blodfortyndende behandling inden for 30 dage efter udskrivelse. De mest robuste 
prædiktorer for ikke at påbegynde behandling var demografiske eller relateret til 
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typen af den venøse tromboemboli, herunder kvinde køn, ung alder, samt dyb 
venetrombose.  
Denne ph.d.-afhandling understreger det fortsatte behov for forbedret behandling 
og håndtering af patienter med venøs tromboemboli. Afhandlingen tydeliggør, at 
recidiv er hyppigt og at mange patienter modtager ingen eller ikke-optimal 
blodfortyndende behandling. Sammen med andre videnskabelige bidrag, kan 
studierne i denne afhandling bidrage til at optimere behandlingsmønstre med 
blodfortyndende medicin for de mange patienter med venøs tromboemboli. 
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BACKGROUND 
INCIDENT VTE 
Venous thromboembolism (VTE) covers both deep vein thrombosis (DVT) and 
pulmonary embolism (PE). DVT is when a thrombus is formed within the deep 
veins. DVT most often occurs in the legs, but can also form in the veins of the arms, 
and in the mesenteric and cerebral veins 1. If a piece of the thrombus is dislodged 
from the deep veins, it can travel to the pulmonary arteries and form a, potentially 
fatal, PE.  
VTE is the third leading vascular disease after myocardial infarction and stroke 2, 
and in 2010 almost 20.000 visits on to Danish hospitals concerned VTE 3. The 
incidence rate of incident VTE is 1-2 per 1000 person-years and rises exponentially 
with increasing age 4. In incident VTE patients, 30-40% debut with a PE 5. 
VTE ranges from incidental, clinically unimportant VTE to massive embolism with 
sudden death. Patients suffering a VTE are at risk of developing chronic 
thromboembolic pulmonary hypertension 6, post thrombotic syndrome 7, recurrent 
VTE 5, and death 8,9. A Danish population-based cohort study from 2014 showed 
that the mortality risks for patients with DVT and PE were markedly higher than for 
an age- and sex-matched comparison cohort without VTE during the first year, 
especially within the first 30 days (3.0% for DVT and 31% for PE versus 0.4% for 
controls) 8. Considering both health-economic consequences as well as individual 
patient consequences, it is a disease of great importance to public health in general 
and the affected citizens 10. 
VTE is a multifactorial disease, involving interaction between intrinsic factors of the 
patient (e.g. age, thrombophilia) and acquired exposures (i.e. surgery, hormone 
treatment, cancer) 11,12. Of demographic factors, increasing age is an established 
risk factor, whereas no consensus exists about whether the incidence of VTE varies 
according to sex 1,11,13. The so-called Virchow’s Triad has delineated the basis for 
understanding the pathogenesis of VTE 14. The theory proposes that VTE occurs as 
a result of: 1) stasis/alterations in the blood flow, 2) vessel wall injury and, 3) 
hypercoagulability (i.e., inherited or acquired hypercoagulable state) [Figure 1 – 
reproduced with permission from Kyrle et al. 15]. Many patients with VTE fulfil one 
or more of Virchow’s Triad and will therefore have a pro-thrombotic state.  
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The traditional concept of separation of risk factors and pathophysiology for VTE 
and atherosclerotic disease is being reconsidered 16. VTE and atherothrombosis 
have shared risk factors and a common pathophysiology that includes 
inflammation, hypercoagulability, and endothelial injury 1. Risk factors for VTE, such 
as cigarette smoking, hypertension, diabetes, and obesity, are often modifiable and 
overlap with risk factors for atherosclerosis 1,17. Despite an overlap of the diseases, 
global public awareness is substantially lower for PE (54%) and DVT (44%) than 
heart attack (88%) and stroke (85%) 18. 
 
The diagnosis of VTE is based on the clinical symptoms, D-dimer level, and relevant 
imaging examination 19. Clinical signs and symptoms of PE and DVT are highly 
variable and unspecific but remain a cornerstone in the diagnostic strategy. 
Symptoms of DVT include pain, swelling, increased skin veins visibility, erythema, 
and cyanosis. In patients presenting with DVT symptoms, approximately 50% will 
have a co-existing PE 19. However, only 5% of the DVT patients with co-existing PE 
will present with symptoms of a PE: including dyspnoea, hypoxia, sinus tachycardia, 
syncope, breast pain or haemoptysis 19. Importantly, VTE patients might also 
present as asymptomatic or mimicking another disease, e.g. exacerbation of 
chronic obstructive pulmonary disease, consequently increasing a potential risk of 
physicians not recognizing the underlying VTE.  
 
 
Figure 1: Virchow’s triad  
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PROVOKED OR UNPROVOKED 
Incident VTE is traditionally categorized as ‘provoked’ or ’unprovoked’ depending 
on factors in the patient’s medical history. In the literature, ‘provoked’ VTE is 
further sub-categorized according to whether the provoking factor was ‘persistent’ 
(i.e., active cancer), or whether the factor was a ‘major transient’ (e.g. surgery, 
immobilization), or ‘minor transient’ factor (e.g. oestrogen therapy, pregnancy, 
trauma/leg injury) 20. ‘Unprovoked’ VTE is when no known provoking factor can be 
identified. Whether an episode of VTE was ‘unprovoked’ or ‘provoked’ has 
important prognostic and treatment implications. Most international guidelines 
base the recommendation of treatment duration on this simple 
dichotomization21,22. Patients with ‘provoked’ VTE are recommended shorter time-
limited treatment whereas patients with ‘unprovoked’ VTE are recommended 
longer (> 3 months) “extended” treatment. Of note, patients with ‘provoked’ VTE 
due to active cancer are also recommended longer treatment duration.  
 
While dichotomizing VTE as provoked or unprovoked, may seem appealing because 
of the apparent simplicity, the clinical picture is often much more nuanced. There is 
a large grey zone where precise categorization is not possible, and the term 
‘provoked’ VTE is not clearly defined making consistent stratification challenging. It 
is well-established that major surgery is associated with VTE 23, and surgery is often 
referred to as ’a major (transient) risk factor’ for VTE. But what about chronic 
inflammatory diseases? And does the recurrence risk then differ according to 
activity of the inflammatory disease? Are all kinds of trauma associated with an 
increased VTE risk? And what about driving a car for 6 hours with or without 
stopping for refuelling? In 2018 the International Society of Thrombosis and 
Haemostasis (ISTH) published a guideline on how to define a risk factor as a 
provoking (transient or persistent) 20. According to the ISTH, a minor transient risk 
factors is: “associated with a 3 to 10-fold increased risk of having a first VTE” or 
“associated with half the risk of recurrent VTE after stopping anticoagulant therapy 
(compared with if there was no transient risk factor), when the risk factor occurred 
up to 2 months before the VTE.” Although surely well intended, this definition can 
be difficult to translate into clinical practise practice. 
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RECURRENT VTE 
Patients with incident VTE are known to carry a considerable risk of recurrence 
with an associated high mortality 8,24. A meta-analysis from 2019 including 18 
studies described a cumulative recurrence risk after ‘unprovoked’ VTE approaching 
36% after 10 years 25. However, VTE patients are heterogeneous and recurrence 
risk varies considerably according to patient characteristics 26–28. Therefore, 
assessment of the VTE recurrence risk after acute VTE is a complex task.  
Factors associated with recurrence include cancer, immobilization, and elevated 
body mass index 17,19. Furthermore, male sex has been consistently associated with 
a higher risk of recurrence 17,29. In a meta-analysis on 2554 patients with incident 
VTE investigating risk of recurrence, it was found that men had a 2.2-fold higher 
risk of recurrent VTE than women 29. It is debated whether elevated D-dimer levels 
after discontinuing anticoagulation is associated with recurrence 30–32. 
Furthermore, it is debated whether recurrence risk depend on the clinical 
manifestation of the incident event (if it is similar after proximal DVT and after PE) 
12,33,34. However, in patients with incident PE, VTE more frequently recurs as PE, 
while in patients who have had incident DVT, it tends to recur more frequently as 
DVT 12. 
Anticoagulation is the keystone in VTE treatment and prevention of VTE morbidity, 
mortality, and recurrence. Anticoagulation is effective during treatment but do not 
eliminate the risk of subsequent recurrence after the discontinuation 35. An 
increased risk of recurrence is found in the first 3- 6 months after anticoagulation 
cessation after which recurrence rates decline 25,33,36. However, while a patients 
individual risk of recurrence may decline over time, the risk for major bleeding 
while treated remains constant 37.  
Optimal duration of anticoagulation is a key issue in VTE management and largely 
dependent on the recurrence risk. However, estimates on recurrence risk after 10 
years follow-up is sparsely investigated and vary widely, ranging from 25% to 40% 
24,25,33,38,39 (see Table 1 for selected key studies on recurrence risk). Comparison 
between studies investigating VTE recurrence risk is challenging due to several 
epidemiologic issues: the definition of ‘provoked’ VTE varies throughout the 
literature; some studies are confined to patients with DVT others to patients with 
PE; the issue of death as a potential competing risk for recurrence has rarely been 
taken into account; and finally, some studies are restricted to patients with 
BACKGROUND 
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‘provoked’ VTE, some to patients with ‘unprovoked’ VTE, and some include both 
types (Table 1). 
The recurrence risk according to the VTE categorization used in guidelines is 
sparsely investigated 39. However, based on available scientific evidence it is 
anticipated that patients with ‘provoked’ VTE represent a low-risk group with 
regards to recurrence of VTE. This is also reflected from the recommendation of 
time-limited duration of anticoagulant treatment in guidelines 21,22. One study 
investigated recurrence risk according to all three VTE types: ‘unprovoked’, 
‘provoked’, and ‘cancer-related’ VTE 39. However, the study only included 166 
patients with cancer – none of which were alive after 10 years. Therefore, they 
were not able to estimate long-term (10 year) recurrence risk for this group. The 
study reported 5-year cumulative incidence proportions: 28% for patients with 
‘unprovoked’ VTE, 14% for patients with ‘provoked’ VTE, and 11% for patients with 
cancer. In conclusion, uncertainty remains in estimates of the long-term risk of 
recurrent VTE if anticoagulation is discontinued 22. This uncertainty is reflected in 
weak (grade 2B) recommendations of the extended treatment to patients with 
‘unprovoked’ VTE.  
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Table 1: Selected studies of VTE recurrence risk 
Study, year 
Follow-
up time 
Type and number of 
incident VTE patients 
Recurrence risk 
Kniffin et al40, 
1994. 
- Unprovoked and
provoked combined:
7,174 PE and 8,923 
DVT.
DVT patients: CIP* (recurrent PE): 3 months: 0.6%, 6 
months: 1.0%, 12 months: 1.7%, 24 months 2.5%. 
PE patients: CIP (recurrent PE): 3 months: 4.8%, 6 
months: 6.3%, 12 months: 8.0%, 24 months 10.1%. 
Schulman et 
al41, 1995. 
24 
months 
Unprovoked and 
provoked combined: 
897 VTE. 
123 recurrences. 
6 weeks treated group CIP 2-years: 18%; 6 months 
treated group CIP: 9.5%.. 
Beyth et al42, 
1995. 
6-8 years Unprovoked and 
provoked combined: 
124 DVT. 
18 recurrences. 
CIP: 1-year: 6%, 5 year CIP: 13%. 
Prandoni et 
al43, 1996. 
2 years  Unprovoked and 
provoked combined: 
355 DVT. 
78 recurrences. 
CIP: 2 years 17.5%, 5 years: 24.6%, 8 years: 30.3%. 
Van Beek et 
al44, 1997. 
6 months Unprovoked and 
provoked combined:  
193 PE. 
14 recurrences (8%). 
White et al45, 
1998. 
6 months 36,924 (provoked?) 
DVT. 
Patients hospitalized for 3, 4, 5, and 6 days, the 6-
month CIP of recurrence was 5.4%, 5.1%, 5.4%, and 
6.0%. 
Heit et al38, 
2000. 
Median 
7.4 years 
Unprovoked and 
provoked combined: 
1,719 VTE. 
404 recurrences. 
CIP: 7 days 1.6%, 30 days: 5.2%, 180 days: 10.1%, 1 
year: 12.9%, 10 years CIP: 30.4%. 
Hansson et al46, 
2000. 
3-23 
months
Unprovoked and 
provoked combined: 
738 DVT. 
109 recurrences (18.4%). 
CIP: 1 year: 7.0%, 2 years: 12.1%, 3 years: 15.0%, 4 
years: 17.9%, 5 years: 21.5%. 
Baglin et al47 
2003. 
24 
months 
Unprovoked and 
provoked combined:  
570 VTE. 
CIP: 2-year: 11%. 
Patients with unprecipitated VTE: CIP 2-year: 20%  
Patients with non-surgical triggers for a first VTE: CIP 2-
year: 8%. 
Prandoni et al24 
2007. 
Median 
50 
months 
Unprovoked:  
864 VTE. 
Provoked VTE: 
(Excl. cancer):  
762 VTE. 
Unprovoked 268 recurrences (31%)  
CIP: 1-year: 15.0% 
Provoked: 105 recurrence (14%)  
CIP 1-year: 6.6% 
Combined CIP: 1 year: 11.0%, 3 year: 19.6%, 5 year: 
29.1%, 10 year: 39.9%. 
Rodger et al48, 
2008. 
(HERDOO2) 
18 
months 
Unprovoked: 
646 VTE. 
91 recurrences (14.09%)  
Annual risk 9.3%. 
Eichinger et 
al49, 2010. 
(Vienna) 
43.4 
months 
Unprovoked:  
929 VTE. 
176 recurrences (18.9%). 
1-year rate: 8.9%.
Tosetto et al50, 
2012. (DASH) 
Median 
22.4 
months 
Unprovoked:  
1,818 VTE. 
Only predicted risks of recurrence according to score 
level. 
Score=1: annual risk: 3.1%, score >1 annual risk:  9.3%. 
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Table 1 
continued 
Study, year 
Follow-
up time 
Type and number of 
incident VTE patients 
Recurrence risk 
Martinez et al 
33, 2014. 
Up to 10 
years 
Unprovoked: 
16,708 VTE. 
Provoked:  
12,073 VTE (Excl. 
cancer). 
Unprovoked: Complete IR: 3.8/100PY** 
Provoked: Complete IR: 5.6/100PY 
Combined: 10-year CIP: 25.2%,  
6-month IR: 11/100 PY, after that: 2/100 PY.
Huang et al51, 
2015. 
3 years Unprovoked and 
provoked combined: 
2,334 VTE. 
CIP: 30 days: 2.9%, 1 year: 7.2%, 3 year: 11%. 
Moreno et al52, 
2016. 
(DAMOVES) 
21.3 
months 
Unprovoked:  
398 VTE. 
65 recurrences (16.3%).  
Only relative risks reported. 
Arshad et al39, 
2016. 
Median 
7.7 years 
Unprovoked and 
provoked: 
710 VTE 
114 recurrences. 
Unprovoked CIP: 5 years: 17.9% 
Provoked CIP: 5 years: 16.7% 
Cancer CIP: 5 years: 26.4%   
Combined CIP: 10 year: 28%. 
Rodger et al53, 
2016. 
Mean 5 
years 
Unprovoked: 
663 VTE. 
165 recurrences. 
CIP: 8-year: 29.6% 
Kahn et al 25, 
2019.  
Review Unprovoked:  
7,515 VTE. 
CIP: 2-year: 16%, 5-year: 25%, 10-year: 36%. 
Timp et al 54, 
2019. 
(L-TRRiP) 
Median 
5.7 years 
Unprovoked and 
provoked:  
3,750 VTE. 
507 recurrences. 
CIP (combined): 2 years: 7.4%, 4 years: 11.7%, 6 years: 
15.0%, 8 years: 17.0%. 
CIP: cumulative incidence proportion, **PY: patient-years. 
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ANTICOAGULANT TREATMENT OF VTE 
The aim of anticoagulation after an acute VTE is initially to prevent growth and 
embolization of the thrombus, and additionally to prevent sequelae, e.g., post 
thrombotic syndrome or chronic pulmonary hypertension 19. This is initially an 
acute treatment that should be given to all patients presenting with VTE 12,55. 
Minimum treatment duration is currently 3 months. The haemodynamically 
instable patient might also initially need reperfusion treatment, e.g. surgical 
embolectomy, percutaneous catheter-directed treatment, or thrombolytic therapy 
12. Uncertainty remains with regard to optimal treatment of patients with isolated
distal DVT where recommendations in guidelines are vague 21,22. However, in
practice, most of these patients are also treated with anticoagulation 56.
For many years, vitamin K antagonists (VKA) were the only available class of oral 
anticoagulants, and therefore the standard of care for VTE treatment. In the last 
decade, non-vitamin K antagonist oral anticoagulants (NOACs) have been approved 
for treatment of VTE. In 2012, rivaroxaban was the first NOAC to be approved for 
VTE treatment in Denmark 57. NOACs have not only intrinsic advantages such as 
rapid onset of action and wide therapeutic windows, but also a lower risk of 
intracranial, and fatal bleeding in VTE patients compared with VKA (i.e. warfarin) 
58,59. Furthermore, NOACs do not require laboratory monitoring and have fewer 
drug and food interactions than VKA.  
The NOACs include the direct thrombin inhibitor dabigatran and direct Factor Xa 
inhibitors rivaroxaban, apixaban, and edoxaban. Treatment with dabigatran and 
edoxaban requires at least 5 days of bridging with low-molecular-weight heparin, 
whereas apixaban and rivaroxaban can be administered directly without heparin 
lead-in (see Figure 2). Until recently, low-molecular-weight heparin was the only 
recommended treatment option for patients with cancer-associated thrombosis, 
but guidelines now include edoxaban and rivaroxaban as treatment options for 
cancer patients with acute VTE, who have a low risk of bleeding and no potential 
drug-drug interactions with current systemic anticancer therapy 12,60–62. 
VENOUS THROMBOEMBOLISM AND RISK OF RECURRENCE 
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Figure 2: Treatment options for VTE 
The 2019 European Society of Cardiology (ESC) guidelines from European Heart 
Journal, recommend use of NOAC as first-choice treatment for VTE in patients 
eligible for a NOAC 12. However, limited data exist on the safest and most effective 
NOAC due to lack of head-to-head trials comparing the NOACs 58,63. The COVET Trial 
(Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism; 
NCT03196349) was set-up to compare warfarin vs. rivaroxaban vs. apixaban for 12 
months of extended treatment after 3-12 months initial treatment for 
‘unprovoked’ VTE. However, according to clinicaltrials.gov recruitment status is 
“terminated (lack of enrolment)” and was “last updated August 2019” (site visited 
November 2019). Consequently, no NOAC is recommended over another. The 
choice of a specific NOAC is often based on physician and patient preferences, 
availability and reimbursement 58. 
EXTENDED TREATMENT 
After the acute treatment period (minimum 3 months), the aim of the extended 
treatment, is to prevent VTE recurrence over the long-term. Oral anticoagulants are 
highly effective in preventing recurrent VTE during treatment, but they do not 
eliminate the risk of subsequent recurrence after the discontinuation of treatment 
35. As shown in the PADSIS-PE (Prolonged Anticoagulation During Eighteen Months
vs Placebo After Initial Six-month Treatment for a First Episode of Idiopathic
BACKGROUND 
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Pulmonary Embolism) trial, the clinical benefit is not maintained when 
anticoagulation is stopped 35. In the PADIS-PE trial, 371 patients with ‘unprovoked’ 
PE were initially treated with warfarin for 6 months. After this period, patients 
were randomized to either additional 18 months warfarin treatment or to placebo. 
During the 18 months treatment period, the study found a hazard ratio (HR) of 0.22 
(95% Confidence Interval (CI) 0.09; 0.55) for the risk of the composite endpoint of 
recurrent VTE and major bleeding in favor of additional therapy. This result was 
driven by a reduction in the risk of recurrent VTE: major bleeding occurred in 4 
patients in the warfarin group and in 1 patient in the placebo group (HR 3.96; 95% 
CI 0.44; 35.89), and recurrent VTE occurred in 3 patients in the warfarin group and 
25 patients in the placebo group (HR 0.15; 95% CI 0.05; 0.43). However, the benefit 
of anticoagulation in reducing recurrence was lost after anticoagulation was 
discontinued. In the 2 years posttreatment follow-up period, the recurrence risk in 
the warfarin group increased. At the end of follow-up, the risk in the warfarin 
group resembled the risk of the placebo group 35. Same results were found when 
repeating the study with patients with DVT instead of PE 64. Hence, time-limited 
treatment durations seem to merely delay but not entirely prevent recurrent 
events 35. However, continuing anticoagulation is associated with a potential harm 
due to the risk of major bleeding, which can be fatal. Hence, optimal duration of 
the extended anticoagulation is both a crucial scientific and clinical concern.  
The relative safety of NOACs over VKAs has led to considerations for extended, 
rather than limited, duration of anticoagulation therapies for VTE 59. Both 
dabigatran, apixaban and rivaroxaban have all been investigated in randomized 
trials for extended treatment (after initial acute treatment in 3-18 months) (Table 
2). Edoxaban has not yet been investigated for extended VTE treatment. The tested 
drugs have all been proven effective in reducing recurrence risk compared to 
placebo, but the benefit is partially offset by a risk of bleeding. Sulodexide and 
acetylsalicylic acid and have also been investigated for extended treatment, but are 
only recommended to patients who refuse to take or are unable to tolerate any 
form of oral anticoagulants 12. Sulodexide is a mixture of low-molecular-weight 
heparin and dermatan sulphate, not standardly used in Denmark. The findings on 
extended therapy suggest a shift of the risk-benefit balance in favour of extended 
treatment.  
Heterogeneity between the NOAC trials complicates indirect comparisons. The 
proportion of patients with ‘provoked’ VTE varies from approximately 60% in 
EINSTEIN-Choice 65 (Reduced-dosed Rivaroxaban in the Long-term Prevention of 
BACKGROUND 
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Recurrent Symptomatic Venous Thromboembolism)  to approximately 8% in 
AMPLIFY-Ext 66 (Apixaban after the Initial Management of Pulmonary Embolism and 
Deep Vein Thrombosis with First-Line Therapy–Extended Treatment) (the 
proportions in RE-MEDY and RE-SONATE are not reported). Duration of the acute 
treatment phase varies from 3-18 months and the duration of the extended period 
varies in a span of 6- to 36 months between the NOAC trials. Consequently, no 
certain answer can be given on which anticoagulant drug to choose to best balance 
the benefit of preventing recurrent VTE and minimize the harms of bleeding.  
To guide treatment duration, American guidelines categorize patients with incident 
VTE as ‘provoked’ or ‘unprovoked’ 22. Extended treatment is recommended to 
patients with low bleeding risk and ‘unprovoked’ proximal DVT or PE and to 
patients with active cancer and low bleeding risk (Table 3) 22. Extended treatment is 
defined as 3 months to indefinite anticoagulant therapy where the continuing use 
of treatment should be reassessed at periodic intervals (e.g., annually), patient 
preference considered, and the choice of anticoagulant regimen re-evaluated 22. 
In the 2019 ESC Guidelines 12 VTE patients are categorized according to the risk of 
recurrence over the long-term in: low risk (<3% per year) comprising patients with 
major transient or reversible risk factors; intermediate risk (3-8% per year) 
comprising patients with transient or reversible risk factors, non-malignant 
persistent risk factors, and no identifiable risk factors; and high risk (>8% per year) 
comprising patients with active cancer, previous VTE, and antiphospholipid 
antibody syndrome (Table 4) [Table reproduced with permission from 
Konstantinides et al. 12]. All patients except those with an estimated “low risk” 
should therefore be considered for extended anticoagulation. These 
recommendations were raised from a recommendation 2b to a 2a in the latest 
guideline update. Linguistically, this means that extended treatment “should” be 
considered instead of “could”. However, whether using the classification 
“provoking” risk factor or the terminology using “transient/persistent” risk factors, 
the dilemma remains on when exactly to define a factor as so.  
Despite advantages of the NOAC’s, underuse of anticoagulation and low 
medication adherence is still a matter of concern 9. Non-initiation of 
anticoagulation is a global challenge that has been demonstrated both among 
patients with atrial fibrillation and VTE. A registry-based study from Denmark 
investigating anticoagulant therapy and mortality after VTE found that 21.3% of PE 
patients and 34.9% of DVT patients did not fill a prescription for anticoagulation 
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within 30 days 9. However, the study did not investigate predictors associated with 
non-initiation to possibly decrease the high proportion of untreated VTE patients. 
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RISK OF BLEEDING 
A meta-analysis on 6 phase 3 trials compared the efficacy and safety of NOAC’s 
versus VKA in the acute treatment of VTE 59. Recurrent VTE occurred in 2.0% of 
NOAC recipients compared with 2.2% in VKA recipients (relative risk (RR) 0.90, 95% 
CI 0.77; 1.06) 59. Furthermore, treatment with a NOAC significantly reduced the risk 
of major bleeding (RR 0.61, 95%CI 0.45; 0.83) 59. In the VTE extension studies on 
NOACs, major bleeding or clinically relevant non-major bleeding occurred in 2-6% 
of the patients in the intervention groups (dabigatran67, rivaroxaban65,68, and 
apixaban 66) (Table 2). In a study from 2014 using data from a prospective, non-
interventional, oral anticoagulation registry of 1,776 daily care patients (Dresden 
NOAC registry) treated with rivaroxaban, major bleeding occurred in 6.1% with an 
annual major bleeding rate of 4.1 (95% CI 2.5-6.4) per 100 patient-years (py) 72. The 
patients were treated with rivaroxaban for a median of 274 days. However, despite 
different treatment regimens, uncertainty remains in estimates of the long-term 
risk of major bleeding if treatment is continued. Also, since patients at high 
bleeding risk were excluded from the NOAC extension studies, the safety of the 
drugs in these patients still needs clarification. 
Several bleeding risk scores have been developed to help evaluate the risk of 
bleeding. Some of the most frequently used bleeding scores include the HAS-BLED 
score 73, originally developed to assess bleeding risk in patients with atrial 
fibrillation using VKAs, the VTE-BLEED score 74, and the ACCP scheme 22. The two 
latter VTE-specific bleeding scores are developed for patients with ‘unprovoked’ 
VTE only.  
Individual studies have validated the predictive performance of the bleeding risk 
scores 75–77. However, a review from 2017 concluded that none of the bleeding 
scores could be used to guide decisions about extended treatment for secondary 
prevention of recurrent event in patients with ‘unprovoked’ VTE 78. Of note, the 
review did not include the HAS-BLED score. The review concluded that the 
discriminatory performance was too poor and that the scores had been 
insufficiently evaluated in appropriate patient populations. They recommended 
that clinicians use clinical knowledge to assess the risk-benefit ratio on well-
established risk factors in this patient population 78. On the contrary, a study from 
2019 evaluated the ability of the VTE-BLEED score using a Japanese multicentre 
registry (the COMMAND VTE Registry) 79. They concluded that the VTE-BLEED score 
could be useful for assessment of bleeding risk and hence the optimal duration of 
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anticoagulation therapy in individual patients 79. In 2019 ESC guidelines, it is 
suggested to reassess bleeding risk periodically (e.g., once a year in patients at low 
risk, and every 3 or 6 months in patients at high risk for bleeding) either by implicit 
judgement after evaluating individual risk factors or by the use of a bleeding risk 
score at the time of initiation of anticoagulant treatment 12. They do not 
recommend use of one score over another. The American guidelines list their own 
(ACCP) scheme to determine bleeding risk 22. 
The newly developed reversal agents for the NOACs may support the paradigm 
shift towards extended treatment duration. Additionally, there is an ongoing search 
for anticoagulants that will exert anti-thrombotic effects without impeding 
haemostasis and thus theoretically without causing major bleeding complications. 
Coagulation factors XI and XII have been identified as promising targets 80. While 
these new targets for anticoagulation are continuously being investigated, the 
search for the optimal duration of anticoagulation for the individual patient 
continues 80.  
RISK STRATIFICATION FOR VTE RECURRENCE 
Treatment of VTE patients should add up to a net clinical benefit in favour of a 
reduced recurrence risk without an excess risk of bleeding. Risk stratification and 
prediction models may aid clinicians in such decision-making situations. Risk 
prediction models have also become increasingly popular in the era of “shared 
decision-making” aiming at including both the patient’s and physician’s perspective 
when deciding on realistic treatment plans. However, despite many models 
published in the academic literature, most models are never translated into useful 
tools for the clinician 81. When developing risk scores, we therefore have to 
consider: “are we just adding to the heap or closing a gap?” 82. 
VTE prediction models have been developed 48–50,52,54 (see Table 5). However, none 
of the existing VTE recurrence risk models are recommended in guidelines and they 
have only been sparsely validated 54,83–86. Therefore, to navigate the dilemma and 
guide anticoagulant treatment duration, most guidelines recommend the basic 
stratification with classification of the incident VTE event as ‘provoked’, ‘cancer-
related’ or ‘unprovoked’ depending on risk factors in patients’ medical history 21,22. 
A clinically useful stratification would identify patients with high risk of recurrence 
requiring continued treatment and, conversely, patients with a shorter, time-
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limited need for treatment. This would enable treating physicians to make the best 
possible choices regarding duration of anticoagulation. However, if this is not the 
case, it will add to the current dilemmas in VTE treatment management.
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UNANSWERED DILEMMAS IN VTE TREATMENT 
As summarized, patients suffering a VTE carry a considerable risk of recurrent 
events. Therefore, incident VTE is initially an acute disease requiring anticoagulant 
treatment despite any other patient comorbidity. Nonetheless, a dilemma arises 
after the initial treatment period of 3 to 6 months: Should we stop or continue the 
anticoagulant treatment? Several aspects influence this decision [Figure 3]. 
Risk of recurrence and bleeding 
The optimal duration of anticoagulation is one of the most vexing issues in VTE 
management and is largely dependent on the VTE recurrence risk. Furthermore, 
the recurrence risk must always be balanced against the risk of bleeding when 
receiving anticoagulation. However, as debated, VTE patients are a heterogeneous 
population with varying recurrence risk. Uncertainty remains of both the long-term 
risk of major bleeding if treatment is continued, and, importantly, the long-term 
risk of recurrent VTE if anticoagulation is discontinued 22. 
Ideally, risk stratification should differentiate patients in groups above and or 
below well-defined risk thresholds that allow guidance of clinical decision-making 
in relation to treatment duration. As reviewed above, most guidelines recommend 
a simplistic dichotomization in ‘provoked’/’unprovoked’ while no clear definition 
for the term ‘provoked VTE’ exists. No other risk stratification tool is recommended 
in guidelines and recommendations remain imprecise with respect to treatment 
duration 12,21,22.     
Figure 3: Dilemmas in VTE treatment 
UNANSWERED DILEMMAS IN VTE TREATMENT 
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Adherence and patient preference 
Adherence to medication is a prerequisite for successful treatment. During the 
shared decision making on anticoagulant treatment duration, patient preference is 
an important aspect to consider to ensure optimal adherence. Despite advantages 
of the NOAC’s, underuse of anticoagulation and low medication adherence is still a 
matter of concern 9. However, no previous studies have investigated predictors of 
non-initiation. 
Research goals 
This thesis is based on three studies ultimately aiming at more informed navigation 
in some of the dilemmas of VTE treatment. The studies focus on various 
perspectives regarding VTE recurrence, from clarifying contemporary VTE 
recurrence risk, developing a new risk stratification tool for recurrent VTE, to finally 
identifying potential predictors of not initiating anticoagulation after incident VTE. 
The thesis will provide a general discussion of issues surrounding recurrent VTE and 
present and debate the results of the three studies within this discussion. When 
referring to one of the papers in the thesis it is highlighted in bold: Study 1/2/3. 
AIMS 
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AIMS 
The specific aims of the studies were: 
Study 1 
The aim of the first study was to describe the risk of recurrent VTE according to 
‘unprovoked’, ‘provoked’ and ‘cancer-related’ incident VTE, representing the 
stratification used in most VTE guidelines. 
Study 2 
The aim of the second study was to develop and internally validate risk prediction 
scores for VTE recurrence for men and women separately, which may aid the 
decision of anticoagulant treatment duration for patients with incident VTE.  
Study 3 
To potentially improve treatment adherence, the aim of the third study was to 
investigate factors associated with not initiating anticoagulation after incident VTE. 
36
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SETTING AND STUDY POPULATION 
Denmark has several advantages when it comes to registration of health data 
making it ideal for epidemiological large-scale cohort studies: 1) citizens with 
residency in Denmark are offered a free-of-charge tax-supported educational- and 
health-care system, where all medications are partly reimbursed; 2) all residents in 
Denmark hold a 10-digit unique identification number 87 enabling individual-level 
cross-linkage of data from numerous nationwide registries; and finally 3) 
government-maintained and funded nationwide registries, providing longitudinal 
sources of routinely collected administrative, health, and clinical quality data 88.  
All three studies of this thesis were based on data from the Danish nationwide 
registries to identify patients with a VTE diagnosis. Via these registries, we had 
information on dates of admission and discharge diagnoses for more than 99% of 
all hospital admissions, sex, date of birth, vital status, and emigration status on all 
citizens; information on purchase date, Anatomical Therapeutic Chemical (ATC) 
classification codes, and package size for all prescriptions claimed; and information 
on socio-economic factors. The registries are described in more detail on page 69. 
Methods used to increase the positive predictive value (PPV) of both incident and 
recurrent VTE diagnoses are described under “Methodological Considerations” on 
page 71. 
SETTING AND STUDY POPULATION 
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STUDY 1 
Study 1 was made in cooperation with: Peter B. Nielsen, Mette Søgaard, Samuel Z. 
Goldhaber, Thure F. Overvad, Lars H. Rasmussen, and Torben B. Larsen 5. 
Aim: In Study 1, we sought to investigate the risk of recurrent VTE according to the 
incident VTE categories suggested in guidelines: ‘provoked’, ‘unprovoked’ and 
‘cancer-related’.  
Methods: Since no clear definition of ‘provoked VTE’ is available, we used available 
literature and guidelines to define ‘provoked”, ‘unprovoked’ and ‘cancer-related’ 
VTE. We linked data from nationwide Danish health registries (described on page 
69) to identify all patients with incident VTE from January 2000 through December
2015. Incidence rates were calculated as number of events divided by 100 py and
the absolute risk of recurrence, with no adjustment for anticoagulant treatment,
was depicted as cumulative incidence functions by means of the Aalen-Johansen
estimator, assuming death as competing risk.
Results: The study population comprised 73,993 patients with incident VTE (54.1% 
female and mean age 62.3 years). In the study population, 49% were categorized as 
having ‘unprovoked’ VTE, 38% with ‘provoked’, and 14% with ‘cancer-related’ VTE. 
At 6-month follow-up, the recurrence rates for patients with ‘provoked’ (6.92 per 
100 py) and ‘unprovoked’ VTE (6.80 per 100 py) were similar (Table 6). Patients 
with cancer-related VTE had a higher recurrence rate (9.06 per 100 py). Recurrence 
rates at 10 years follow-up were 2.84 per 100 py for patients with ‘unprovoked’ 
VTE, 2.22 for patients with ‘provoked’ VTE, and 3.70 for cancer-related VTE.  
At 6-month follow-up, the absolute recurrence risk for patients with ‘provoked’ and 
‘unprovoked’ was similar (Figure 4A). Highest recurrence risk was found for 
patients with cancer. The cumulative incidence curve for patients with ‘provoked’ 
VTE diverged just after the 6-month mark, with an estimated absolute recurrence 
risk at 10-year follow-up of 15%. At the 10-year follow-up, the risks of ‘unprovoked’ 
and ‘cancer-related’ VTE were similar, with an absolute recurrence risk of 
approximately 20% for both types of VTE (Figure 4B) 5.    
Conclusion: This study found that patients with ‘cancer-related’ VTE possessed the 
highest recurrence risk. At 6-month follow-up, risk of recurrence for patients with 
‘unprovoked’ and ‘provoked’ VTE was similar. At 10-year follow-up, the risk of 
recurrence was comparable for patients with ‘unprovoked’ VTE and patients with 
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‘cancer-related’ VTE. A high recurrence risk in all types of VTE – including 
‘provoked’ VTE – underscores that further research is needed to optimize risk 
stratification for VTE patients 5.
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DISCUSSION AND PERSPECTIVES (STUDY 1) 
Other studies reporting incidence rates show the same tendencies as found in 
Study 1 with highest recurrence rates in the first months after incident VTE 
25,33,39,89. In line with our findings, a meta-analysis from 2019 on 18 studies 
investigating recurrence risk after ‘unprovoked’ VTE in patients discontinuing 
anticoagulation, described a 10-year recurrence rate similar to what we found of 
3.1 per 100 patient years 25. Their estimated cumulative risk of recurrence of 36% 
(95% CI 28%; 45%) after 10 years was somewhat higher than what we observed. 
Importantly, the review did not consider death as a competing event leading to 
possible overestimation of risk estimates 90. Furthermore, only 3 of the 18 studies 
included in the meta-analysis provided 10 years of follow-up, and half of the 
studies were based on data more than a decade old. 
As previously described, patients with ‘provoked’ VTE are traditionally considered 
at low risk for recurrence. However, in Study 1, we observed a similar recurrence 
risk among patients with ‘provoked’ and ‘unprovoked’ VTE during the first 6 
months of follow-up. After this, the risk curves diverged to some extent. At 10-year 
follow-up, the recurrence risk for patients with ‘provoked’ VTE resembled the risk 
for patients with ‘unprovoked’ and cancer-related VTE. The patients with 
‘provoked’ VTE are expected to be the low-risk group and yet, more than 15% had 
recurrence after 10-year follow-up. 
The EINSTEIN-CHOICE trial 65 randomized patients with incident ‘provoked’ (60%) or 
‘unprovoked’ (40%) DVT and/or PE who had completed 6-12 months anticoagulant 
treatment to either rivaroxaban (20 mg once daily or 10 mg once daily) or low-dose 
aspirin (100mg once daily). The study was in line with our observations by showing 
that the suspected ‘low-risk’ group had a high recurrence risk (see Table 7). In the 
group treated with 20mg rivaroxaban, 1.4% of the patients with ‘provoked’ VTE 
had recurrence one year after randomization, compared with 1.8% of the patients 
with ‘unprovoked’ VTE. In the aspirin arm, 3.6% of the patients with ‘provoked’ VTE 
had recurrent VTE versus 5.6% of the patients with ‘unprovoked’ VTE.  
STUDY 1 
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Table 7: Proportions of recurrent VTE one year after randomization in the 
EINSTEIN-CHOICE trial 65 
EINSTEIN-Extension (Once-daily Oral Rivaroxaban versus Placebo in the Long-term 
Prevention of Recurrent Symptomatic Venous Thromboembolism) was a 
randomised trial comparing rivaroxaban with placebo for 6 or 12 months in DVT 
patients who had completed 6 to 12 months of treatment for VTE 68. Prins et al. 
conducted a study 91 based on data from the EINSTEIN-CHOICE study 65 and the 
EINSTEIN-Extension study 68 to assess the risk of recurrence according to baseline 
profiles defined according to ‘provoked’ VTE further sub-divided in major/minor 
‘transient’ or ‘persistent’ risk factors. They found that the risk of recurrent VTE in 
patients with trauma or major surgery (being ‘major transient’ risk factors) was 0% 
in both the rivaroxaban and aspirin groups. However, risk of recurrence in patients 
with VTE provoked by ‘minor persistent’ (e.g. congestive heart failure, 
inflammatory bowel disease) or ‘minor transient’ risk factors (i.e. immobilization, 
use of oestrogen therapy, pregnancy) were similar to the recurrence risk described 
in patients with ‘unprovoked’ VTE (1.8% and 0.4% versus 1.5% among patients 
treated with rivaroxaban).  
Our conclusion from Study 1, with the findings of high recurrence risk both among 
patients with ‘provoked’ and ‘unprovoked’ VTE, were in line with the findings of the 
EINSTEIN-CHOICE and Prins et al. studies, underscoring that more research is 
needed to optimize risk stratification for VTE patients. 
LACK OF DIFFERENTIATION 
Another aspect to the dilemma of VTE recurrence and risk stratification arises, 
when it appears that ‘provoked’ VTE is also associated with high recurrence risk 5,65. 
This group is traditionally considered low-risk and only recommended time-limited 
anticoagulation for 3 months. Nevertheless, our finding of recurrence risk higher 
than 15% at 10 years among patients with provoked VTE in Study 1 argues against 
Rivaroxaban, 
20mg (N=1107) 
Rivaroxaban, 
10mg (N=1127) 
Aspirin, 
100mg (N=1131) 
Provoked VTE (60%) 1.4% 0.9% 3.6% 
Unprovoked VTE (40%) 1.8% 1.5% 5.6% 
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this common belief. Conversely, guidelines recommend extended treatment for 
patients with ‘unprovoked’ and cancer-related VTE, who had a 10-year recurrence 
risk of approximately 20 % in Study 1. Ideally, risk stratification should differentiate 
patients in groups above and or below well-defined risk thresholds that allow 
guidance of our clinical decision-making in relation to treatment duration. The 
appreciable recurrence risk in the group of patients with ‘provoked’ VTE revealed in 
Study 1, certainly indicate that optimal VTE management could benefit from a 
more nuanced approach. Either we are bound to consider anticoagulants to 
patients with provoked VTE for a longer period of time, or otherwise we have to 
redefine our approach to risk stratification in order to identify those patients with a 
net clinical benefit justifying short-term treatment. 
A REVISED STRATEGY FOR VTE RISK PREDICTION 
The finding of a high recurrence risk seen across all VTE types combined with the 
continued challenge of how to define ‘provoked’ VTE, inspired the On my Mind 
piece published in Circulation in 2018: “Let’s stop dichotomizing venous 
thromboembolism as provoked or unprovoked”92, see Figure 5. That article was 
done in cooperation with Gregory Piazza and Samuel Z. Goldhaber. 
46 
Figure 5: Revised strategy for determining the optimal duration of 
anticoagulation after VTE 92. 
The underlying idea is that determination of optimal duration of anticoagulation 
should be based on assessment of a patient’s individual risk factors instead of a 
simplistic dichotomization. Refinement of the categories may improve 
identification of those patients with high recurrence risk who needs extended 
duration anticoagulation. Correspondingly, advanced risk stratification could also 
lead to improved identification of patients with a low recurrence risk, who can 
safely discontinue their treatment without fearing recurrence.  
This idea was later on supported by the 2019 ESC guideline on the diagnosis and 
management of acute pulmonary embolism that “no longer support the 
terminology ‘provoked’ and ‘unprovoked’, as it is “potentially misleading and not 
helpful for decision-making regarding the duration of anticoagulation” 12.  
VENOUS THROMBOEMBOLISM AND RISK OF RECURRENCE 
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Altogether, this laid the foundation for the idea of a new prediction model to 
estimate recurrence risk after both ‘provoked’ and ‘unprovoked’ incident VTE. 
VENOUS THROMBOEMBOLISM AND RISK OF RECURRENCE 
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STUDY 2 
STUDY 2 
Study 2 was made in cooperation with: Mette Søgaard, Samuel Z. Goldhaber, 
Gregory Piazza, Flemming Skjøth, Thure F. Overvad, Torben B. Larsen, and Peter B. 
Nielsen 93. 
 Aim 93: Study 2 aimed to develop and internally validate two clinically applicable 
sex-specific prediction models for assessing VTE recurrence risk among patients 
with incident VTE, disregarding the traditional division in ‘provoked’ and 
‘unprovoked’ VTE. 
Methods 93: Using the Danish registries, we identified all cancer-free routine care 
inpatients and outpatients with completed oral anticoagulant treatment for 
incident VTE from January 2012 through December 2017. The outcome was 
recurrent VTE within 2 years (the study design is depicted in Figure 6). Start of 
follow-up was at the time of discontinuation of oral anticoagulation, with a 
maximum treatment period of 1.5 years. Two sex-specific risk scores were derived 
using a Cox regression analysis and a backward selection process on a set of 24 
potential predictors. Performance of the models was assessed through calibration 
and discrimination using bootstrap techniques to internally validate the scores.  
Figure 6: Timeline of Study 2 93. 
Results 93: The study included 11,519 incident VTE patients with completed OAC 
treatment, 53.4% were men and the mean age was 62.6 years. Among men, 
589 (10%) suffered recurrent VTE during two years of follow-up; for women, the 
50
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number was 377 (7%). We developed risk scores under the joint acronym AIM-SHA-
RP (Table 8). Predictors for both sexes were: Age, Incident pulmonary embolism, 
and recent Major surgery; predictors specifically for men were: Statin treatment, 
Heart disease and Antiplatelet treatment, while chronic Renal disease and recent 
Pneumonia or sepsis were predictors specifically for women. Both risk scores were 
well calibrated (Figure 7) and they identified a low-risk group with recurrence risk 
of <5% (3% men, 7% women), a group with intermediate recurrence risk between 
5-10% (7% men, 73% women), and a group with high recurrence risk of >10% (90%
men, 20% women) for both sexes. Generally, discriminative capacities, as measured 
by the c-statistic, were modest.
Conclusion 93: We developed two new risk prediction scores under the joint 
acronym AIM-SHA-RP for men and women. The models were designed to disregard 
the traditional division in ‘unprovoked’ and ‘provoked’ incident VTE. Age, Incident 
PE, recent Major surgery, Statin treatment, Heart disease, Antiplatelet treatment, 
chronic Renal disease and recent Pneumonia/sepsis were all included in the scores. 
These new risk scores may prove useful as tools for shared decision making to 
guide the duration of anticoagulation after incident VTE in everyday clinical practice 
93. 
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Table 8: Final scores for 11,519 men and women 93. 
AIM-SHA-RP: Age Incident PE Major surgery –  
Statin Heart disease Antiplatelet – Renal disease Pneumonia/sepsis 
Men ♂ Women ♀ 
Variable Points Variable Points 
Age > 50 years +1 Age > 60 years +2
Incident pulmonary embolism +1 Incident pulmonary embolism +1
Recent Major surgery* -2 Recent Major surgery* -2
Statin treatment|| -1 Chronic Renal disease‡ -1
Previous Heart disease§ +1 Recent Pneumonia or sepsis† -1
Antiplatelet treatment|| -1
Score sum Score sum 
Low risk: <5% < -1 < 0 
Intermediate risk: 5-10% -1 0-2
High risk: >10% > -1 > 2
*Within 3 months operation with following operation-codes: KA, KB, KD, KF, KG, KH, KJ, KK, KL, KM, KN,
KP, KMCA
§Within 10 years: stroke, cardiac arrest, ischemic heart disease or congestive heart failure, ICD-10 codes: 
I60, I61, I62, I63, I64, I46, I20 I21 I22 I23 I24 I25, I50, I110, I130, I132, I420
||Treatment within one year before incident VTE, ATC-codes: antiplatelet: B01AC04, B01AC06, statins: C10
†Within 3 months hospitalized with sepsis or pneumonia, ICD-10: A40, A41, J12, J13, J14, J15, J16, J17, J18
‡Within 10 years: chronic kidney disease, unspecified kidney failure, chronic nephritic syndrome, or chronic
tubulointerstitial nephritis, ICD-10: N00, N01, N03, N05, I12, I13, I15.0, I15.1, N11, N14, N15, N16, Q61.1-
61.4, N18, N19, N26, N27, N07, N08.
STUDY 2 
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Figure 7: Observed and predicted risk of recurrent VTE for men and women 
according to AIM-SHA-RP score levels 93. 
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DISCUSSION AND PERSPECTIVES (STUDY 2) 
The two new prediction models developed in Study 2 are intended to be used as a 
tool for shared decision-making based on predictions of future risk for recurrent 
VTE both for patients presenting with ‘unprovoked’ and ‘provoked’ VTE. This is in 
contrast to most previous prediction models for VTE recurrence developed only for 
patients with ‘unprovoked’ VTE 48–50,52. Study 2 identified, for both sexes, a low-risk 
group defined as an estimated 2-year recurrence risk of < 5%, an intermediate risk 
group with an estimated 2-year recurrence risk between 5-10%, and a group with 
high recurrence risk, defined as >10% 2-year recurrence risk. 
Low recurrence risk 
Treatment of VTE with a NOAC compared with warfarin has been found to reduce 
the risk of major bleeding 59. However, limited data exist regarding safety of the 
agents in extended periods beyond 6 to 36 months 63. As NOACs may be proven 
increasingly safe for extended treatment, the tipping-point of who to offer 
extended treatment may be shifted towards an even lower threshold, e.g. > 3% 
recurrence risk after 2 years. Until a new threshold is defined, the AIM-SHA-RP 
scores may support the decision to discontinue treatment for patients in the low-
risk groups. Patients with an estimated low risk of < 5% recurrence risk should not 
continue anticoagulation treatment according to contemporary guidelines 94. In 
Study 2, the low risk group comprised 3% men and 7% women.  
Intermediate recurrence risk 
The groups identified with intermediate risk (7% men, 73% women) should be 
advised to continue treatment, but also continue yearly reassessment in order to 
evaluate if new risk factors develops. Importantly, this re-evaluation should 
consider both VTE recurrence risk and bleeding risk to determine the continuous 
optimal net clinical benefit for the duration of treatment.   
High recurrence risk 
Much focus has been on identifying patients who can safely stop their 
anticoagulation after the initial treatment period. However, for many patients, risk 
of recurrence remains high also after anticoagulation discontinuation 5,25. In Study 
2, 90% of the men and 20% of the women were categorized has high risk. The new 
risk scores in Study 2 may support the clinical decision to suggest continued 
treatment for these patients until yearly reassessment discovers a changed clinical 
picture, e.g., newly discovered increased bleeding risk. 
STUDY 2 
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Other VTE prediction models 
One of the existing prediction models focused on risk prediction for women only 
(HER DOO2) as the investigators were unable to identify men with a low recurrence 
risk (see Table 5 on page 31). In the remaining models 48–50,52,54, male sex was a 
predictor of higher risk of recurrence. As in Study 2, the L-TRRiP study found 
surgery to be a predictor of lower risk of recurrence 54. Two models found higher 
age to be predictive of recurrence 48,52, whereas the DASH model described age < 
50 years to be associated with higher recurrence risk 50. In the L-TRRiP study, age 
was not selected in the backward selection process. In their development cohort, 
the mean age was 48 years, while in their validation cohort the mean age was 66 
years, which was similar to our mean age in Study 2. D-dimer either on or after 
anticoagulant treatment was included in most models, with the exception of two of 
the models in the L-TRRiP study 54. 
Similarly to the AIM-SHA-RP model, the L-TRRiP study included patients both with 
‘unprovoked’ and ‘provoked’ VTE 54. However, their models require extensive 
laboratory blood testing and may thus be considered impractical for routine clinical 
care. Whether to aim for a model that is clinically applicable using readily available 
parameters, or to aim for a perhaps more precise and nuanced model requiring 
apps or electronic devises for calculation may be partly determined by data 
available for development – partly by personal preferences. Notwithstanding, 
prediction models should never rule out good clinical consideration.
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VALIDATION OF PREDICTION MODELS 
C-statistic
Validation is an important aspect in the process of predictive modelling. When both
presenting and evaluating prediction models, much attention has solely been on
the C-statistic. This is, however, a simplistic way of assessing prediction model
performance 95. When making qualified decisions on treatment duration of
anticoagulation, an important feature of a model is to be well-calibrated (the
predicted recurrence risk corresponds well with the actual observed risk of the
patient) while consistently stratifying patients below and above well-defined
treatment decision thresholds 95. In the context of VTE, the central question is
whether or not to continue anticoagulant treatment. To answer this, the patient’s
estimated future absolute risk of recurrence is required. In Study 2, the models
Text box: Relevant definitions when validating prediction models 81,133 
Calibration refers to the agreement between observed outcomes and 
predictions from the model. Calibration can be visualized on a calibration- or 
‘validation’ plot, or formally investigated using statistical tests. 
Discrimination refers to a prediction model’s ability to discriminate between 
those with and those without the outcome of interest. The concordance (C) 
statistic is the most commonly used performance measure to indicate the 
discriminative ability. The C-statistic ranges from 0.5 to 1. A value of 0.5 
indicates no discriminative ability (like tossing a coin), and values above 0.5 
indicate positive discriminative ability, where 1 is perfect discrimination. 
Internal validation aims to test if predictions are valid for subjects from the 
underlying population. Apparent performance refers to validation assessed 
directly in the sample where it was derived from. Internal validation can be 
done using various statistical techniques, e.g., bootstrap validation, and split-
sample validation. 
External validation is referring to the generalizability or transportability of the 
prediction model to other populations with the same disease. The external 
validity should be tested in samples fully independent from the development 
data. Preferably, the external validation should be both temporally, and 
geographically different, and performed by different authors ensuring fully 
independent validation.   
STUDY 2 
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were well calibrated (Figure 7) but the discriminative power in terms of C-statistics 
was low. 
An example of a widespread model used in clinical practice despite moderate 
discriminative power is the CHA2DS2-VASc score for atrial fibrillation patients 96. In 
development, the model had a C-statistic of 0.601. However, as in VTE, the 
important key issue is more whether the model allows for stratification below and 
above a decision threshold more than the discrimination. When using the CHA2DS2-
VASc score, patients are to be considered for life-long anticoagulation if they reach 
a certain score threshold (score ≥ 1 for men and score ≥ 2 for women) 97. 
Previous recurrent VTE prediction models 
Previous recurrent VTE prediction models have been sparsely externally validated 
54,83–86 (see Table 8). Some studies did temporal external validation 83,86, others did 
geographical external validation 54,84,85. In the external validation of HER DOO2, it is 
unclear whether the validation was performed using different countries and/or 
centres, or if there was a geographical overlap with the centres used in the 
development of the model 83. The external validation studies were based on 8 
recurrent events in the smallest study (DAMOVES) 86, and 123 recurrent events in 
the largest study (DASH) 84. In the validation study of the Vienna model 84, the first 
author of the original developed model was co-authoring the validation study 84. In 
the remaining validation studies, same first author of the original developed model 
was also first author of the external validation study 54,83,85,86. Hence, none of the 
models have been, by definition,  fully independently validated 81. The 
discriminative capacitive ranges from C-statistics of 0.54 to 0.83. In the external 
validation of HERDOO2, no plots were shown nor was statistical testing performed 
to assess the calibration of the model 83. External validation of the DAMOVES 
model was done in an accompanied publication in a “Letter to the Editor” 86. Here, 
calibration performance was reported with a p-value of 0.125 from a Hosmer-
Lemeshow test without any plots 86. In the study by Timp et al., four prediction 
models were developed with varying complexity 54. In the development study, they 
also performed external validation using another cohort. However, external 
validation could only be done on two out of the four models because laboratory 
markers for the remaining models were not available in the validation cohort. 
Future validation 
In Study 2, internal validation was assessed through calibration and discrimination 
using bootstrap techniques 98. Before used in clinical practice, the developed scores 
STUDY 2 
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should be externally validated in other cohorts. Furthermore, future validation 
studies could, beyond standard external validation procedures, try to add relevant 
factors (e.g., validated codes for trauma with fracture, relevant biochemical 
measures such as d-dimer) to the developed scores and evaluate possible 
optimized performance measures. Importantly, risk estimates for the individual 
patient should be robust and well-calibrated, both in the derivation study but also 
in future validation studies. 
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ADHERENCE 
Adherence to a medication regimen is generally defined as the extent to which 
patients take their prescribed medication 99. Medication adherence is influenced by 
numerous factors, including socioeconomic factors, the healthcare team/system, 
characteristics of the disease, and patient-related factors 99–102. Furthermore, 
medication costs and insurance coverage have been described as rather consistent 
predictors of medication adherence 101,103.  
Poor adherence to medication regimens accounts for considerable worsening of 
disease and death 99. A Cochrane review from 2002 found that increasing medical 
adherence may have a far greater impact on the health of the population than any 
improvement in specific medical treatments 104. Although the NOAC’s offer some 
advantages, underuse of anticoagulation is still an issue of concern 9. However, 
despite adherence being a key factor for successful treatment, no previous studies 
have investigated patient-related predictors of non-initiation. 
For VTE recurrence risk investigated in Study 1, we observed a substantial lower 
number of patients in a sub-analysis restricted to VTE patients initiating 
anticoagulation within 10 days after discharge, indicating potential underuse. This 
inspired the development of the third study aiming to investigate possible 
predictors of not initiating anticoagulation after incident VTE. 
ADHERENCE 
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STUDY 3 
Study 3 was made in cooperation with: Samuel Z. Goldhaber, Gregory Piazza, Thure 
F. Overvad, Peter B. Nielsen, Torben B. Larsen, and Mette Søgaard 105.
Aim: In Study 3, the aim was to investigate incidence of possible predictors for not 
initiating anticoagulation after incident VTE. 
Methods: We linked Danish nationwide health registries to identify all patients with 
incident VTE who were free from cancer from 2003 through 2016. The cohort entry 
was set to the earliest time of available socio economic data (year 2003). Patients 
were defined as ‘non-initiators’ when not redeeming a prescription for 
anticoagulation within 30 days after the incident VTE, including heparin, warfarin, 
phenprocoumon, or a NOAC. Conversely, VTE patients redeeming a prescription in 
this period were defined as ‘treatment initiators’. To identify potential predictors of 
non-initiation, relative risks with 95% CI were calculated using a log-link function 
including other covariates associated with adherence. As potential predictors for 
not initiating treatment, we investigated (i) demographic factors, (ii) socio-
economic factors, (iii) major chronic diseases, (iv) condition-related factors, and (v) 
concurrent medication use. To explore if introduction of NOACs affected the 
proportion of untreated patients, an additional analysis was performed examining 
the study period before and after year 2012 (corresponding to introduction of the 
first NOAC drug, rivaroxaban, approved for VTE treatment in Denmark) 57. We 
further examined the specific types of anticoagulant drugs used from year 2012-
2016. 
Results 105: The final study population comprised 38,044 incident VTE patients. A 
total of 24.1% (n=9,294) did not initiate anticoagulant treatment within the first 30 
days. Most robust predictors of not initiating anticoagulant treatment were 
demographic and condition-related factors, including: age < 30 years, female sex, 
incident DVT, ‘unprovoked’ VTE, and hospitalization < 4 days, whereas 
socioeconomic factors had less influence on the risk of non-initiation (Figure 8). 
Heart failure, ischemic heart disease, and liver disease were also predictors for not 
initiating treatment. Suffering from multiple chronic diseases was not associated 
with anticoagulant treatment non-initiation. The proportion of patients not 
initiating anticoagulant treatment remained virtually unchanged when stratifying 
by calendar period; 2003-2011 (25.2%) and 2012-2016 (23.1%) (Figure 9). Until 
2012, warfarin was the primary anticoagulant drug used. Thereafter warfarin was 
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partly replaced by NOACs, of which rivaroxaban accounted for 23.6% of the total 
anticoagulant drug use and 86.1% of the total NOAC use (Figure 9) 105.   
Conclusion: Up to 24% did not initiate anticoagulant treatment 30 days after 
discharge with incident VTE. Predictors of non-initiation found were DVT, 
‘unprovoked’ VTE, age < 30 years, hospitalization < 4 days, and female sex 105. 
Improving information or treatment follow-up strategies for patients with these 
specific characteristics may improve treatment adherence 105.
62 
Figure 8: Adjusted relative risk of characteristics associated with not initiating 
anticoagulation within 30 days of incident VTE 105. 
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DISCUSSION AND PERSPECTIVES (STUDY 3) 
Medication costs tends to affect adherence101,103. In our study, however, we did not 
find socio-economic factors to be predictive of non-initiation. This could be due to 
the fact that Denmark has a free-of-charge tax-supported health-care system, 
where all medications are partly reimbursed, possibly making the social gradient 
less pronounced. However, despite our developed healthcare system, 
anticoagulant treatment is generally not optimal. In a Danish study comprising 
116,051 atrial fibrillation patients, only 63% of outpatients and 42% of inpatients 
initiated oral anticoagulant treatment 6 months after discharge 106. Furthermore, in 
Danish studies of atrial fibrillation patients with a life-long treatment indication, the 
proportion of anticoagulation discontinuation ranges from 26% to 38% after 3 
years 57,107. Similarly, a Canadian study reported that 26% of 40,776 VTE patients 
not were dispensed with anticoagulation following a VTE diagnosis 108. In an 
American study of treatment patterns and outcomes among hospitalized patients 
with VTE, a non-initiation proportion of 40% was found 109.  
The association of sex and adherence has previously been described as either 
neutral or with females being less compliant 101,103. In our study, we found female 
sex to be a predictor for not initiating treatment. In a Dutch study on NOAC 
persistence in patients with atrial fibrillation, female sex, and no concomitant drug 
use were predictors for non‐persistence 110. Of note, in our study, we cannot 
exclude the possibillity that the PPV of the incident VTE diagnosis may differ for 
example between men and women, potentially explaining the observed sex-
specific association towards non-initiation. 
In our study, patients with DVT were more likely to be non-initiators than patients 
with PE. A recent American study confirmed an association of VTE-type and 
anticoagulant treament: 94% of patients with PE were discharged with 
anticoagulation compared to 87% of patients with lower extremity thrombosis 111. 
However, discharging with treatment is not necessarily equivalent to patients 
continuing treatment or even initiating treatment after their hospital-managed 
medicine during admission. Hence, the proportion of patients acutally on 
treatment might be lower 30 days after discharge. A Dutch study described a 2-
month cumulative incidence of completely stopping NOAC of 20% for patients with 
an acute VTE112. The study only looked at patients initiating treatment, while 
patients never initiating treatment was not invetigated. 
STUDY 3 
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Medical adherence is typically higher in patients with acute conditions as opposed 
to patients with chronic diseases, especially when treated with simple dosing 99,103. 
Nonetheless, we found that almost 1 in 4 did not initiate anticoagulant treatment 
for incident VTE, even after introduction of the NOACs. No obvious explanation 
exists for the relatively high proportion of untreated patients. However, this could 
indicate that medication adherence is a multifaceted challenge with no easy 
solutions. We probably should seek solutions at both at the individual level and the 
system level. 
IMPROVING ADHERENCE 
Some research on optimizing medication adherence exists. A meta-analysis from 
2016 found that mobile phone text messaging approximately doubled the odds of 
medication adherence in patients with chronic diseases 113. A Swedish study 
investigated the effect of a telephone call one week after a cardiovascular 
prescription filled at the general practitioner. In total, 95% (n=174) of the patients 
receiving a phone call filled their prescriptions, as opposed to 87% (n=188) in the 
control group. The analysis showed that primarily women were affected by the 
telephone call 114. For patients treated with rivaroxaban or apixaban for acute VTE, 
a phone call could be at the critical point when shifting from high to reduced dose 
medication 115. From an academic perspective, one attempt to reduce the 
proportion of non-initiators could be a formally developed risk stratification model 
using patient characteristics to determine future risk of non-initiation.  
In Denmark, it is recommended that possible extended anticoagulant treatment of 
VTE patients is evaluated at a follow-up visit after the initial 3-6 months treatment 
19. This recommendation is, however, implemented differently across hospitals.
Some patients are followed-up by cardiologists, others by internal medicine
departments, some by a general practitioner, and some are likely not followed-up
at all. Presumably, adherence could benefit from a more uniform follow-up
structure.
A vital responsibility lies with the clinicians treating and diagnosing VTE patients. 
More focus is necessary on patient education, emphasizing the nature and severity 
of the disease. Improved communication between physician and patient, and more 
frequent follow-up visits could also be areas to work with. Before more knowledge 
and research is available on how to best improve adherence, easily available 
67 
predictors from our study could be used to flag up patients with a high risk of being 
left untreated after hospital discharge. Improving information or treatment 
approaches for patients with these specific characteristics may improve treatment 
patterns. 
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 METHODOLOGICAL CONSIDERATIONS 
All three studies forming the basis for this thesis used information from national 
Danish registries. A brief description of the relevant registries can be found in the 
Text box below (also described in the studies5,93,105). The Education Registers and 
Income Statistics Registries were only used in Study 3. As in all observational 
studies, systematic errors may affect the validity of our findings. We must 
therefore critically evaluate alternatives to causal interpretation when evaluating 
our findings. 
THE DANISH REGISTRIES 
Text box: Administrative nationwide registries used in study 1-3 
The Danish Civil Registration system 87 established in 1968 holding information 
on sex, date of birth, vital and emigration status on all Danish residents. In 
Denmark, all residents are assigned a unique national identification number 
(Central Person Register/CPR-number) at birth or upon immigration allowing 
for individual-level linkage of data from all national registries. 
The National Patient Register 134 established in 1977, which includes dates of 
admission and discharge diagnoses classified according to the International 
Classification of Diseases (ICD) for more than 99% of hospital admissions in 
Denmark. In Denmark, ICD-8 was used from 1977 through 1993 and ICD-10 
from 1994 and onwards. Since 1995, information from emergency room 
contacts, and hospital outpatient clinics has also been recorded.  
The Danish National Prescription Registry 123, containing individual-level 
information on purchase date, Anatomical Therapeutic Chemical (ATC) 
classification codes, and dose units for all prescriptions claimed since 1994. 
The Danish Education Registers 135 holding information on highest completed 
education for 96% of the Danish population aged 15–69. 
The Danish Income Statistics Registry 136 holding information on personal 
income and transfer payments dating back to 1970. Among other, the register 
contains information on average gross income (income subject to ordinary 
taxation - calculated by Statistics Denmark), and taxable income. 
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STRENGTHS AND LIMITATIONS OF THE DANISH REGISTRIES 
Danish registries are well-known for their nationwide coverage with complete 
follow-up in epidemiological terms basically making Denmark an “entire cohort” 116. 
Population-based cohort studies is a specific category of epidemiology studies 
where a defined population is followed up and observed longitudinally to assess 
exposure and outcome relationships 117. Observational cohort studies are designed 
with the capacity to address a wide range of research topics that can be 
generalized to a community or an even broader population than e.g. a cohort 
enrolled in a randomized controlled trials can 117.  
 
The Danish registries offer great advantages and strengths. In general, the number 
of patients is large minimizing the risk of random variation meaning that the results 
are less likely to be due to chance. The registers are well-established, offer almost 
full follow-up and include a large amount of health-related information, which, 
when used wisely, may help close knowledge gaps or identify options for treatment 
optimization. However, even though the well-developed registries are a 
tremendous resource in research, they also come with some limitations. 
 
Register-based research is dependent on complete and valid coding of diseases. 
Inherited thrombophilias is an example of diseases with expected incomplete 
coding. It is estimated that 25% of VTE patients have a Factor V Leiden mutation, 
and 3% suffer from Protein C deficiency 118. However, in Study 2 only 0.4% had a 
thrombophilia code (among other covering both Factor V Leiden heterozygote and 
–hemizygote, prothrombin mutations, protein C and S deficiencies, and 
antiphospholipid antibody syndrome). Despite low completeness, the PPV may still 
be high. In epidemiological terms, this means that the sensitivity of an 
administrative diagnostic code for identifying thrombophilia is low. 
 
Another challenge is when potentially relevant diseases or conditions do not have a 
code in the registries. In the field of VTE, it could be relevant with separate codes 
for proximal/distal DVT, codes for long haul flights, and codes for family history of 
VTE, but none of these conditions have an ICD-code. In some situations, this can 
partly be solved by using proxies, e.g. using chronic obstructive pulmonary disease 
as a proxy for smoking. This is, however, more unspecific and the accuracy of the 
proxy is dependent on the strength of the association between the measured proxy 
and the condition of interest. 
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INFORMATION ISSUES – VTE DIAGNOSES IN THE REGISTRIES 
Despite the use of well-established registries, internal validity of observational 
studies can still be threatened by bias. In epidemiological studies, erroneous 
information collected about the study subjects may result in misclassification of the 
exposure or the outcome (information bias) 119. The PPV of both incident and 
recurrent VTE diagnoses in Danish registries have been validated 120–122. Generally, 
the PPV of VTE diagnoses are low when coded in emergency wards (31%) 122. These 
codes are not included in any of the studies in this thesis. The PPV of VTE diagnoses 
coded in wards, on the other hand, are higher 121.  
Incident VTE: Highest PPV for VTE codes is found when limiting to diagnoses coded 
in combination with a relevant imaging examination (e.g. CT-scan or ultrasound), as 
done in Study 1 and 3 (see Table 9). For incident VTE, this ensures a PPV of 91% 121. 
Consequently, of the patients included with a presumed incident VTE, 9% may be 
misclassified and never had the event. These patients will have a lower risk of 
recurrence (compared to patients with previous VTE) and lower the total estimated 
recurrence risk (Study 1), or they will rightly not initiate anticoagulation (Study 3) 
since they never have had a VTE. Validity of incident VTE diagnoses can also be 
ensured by restricting to VTE patients initiating anticoagulation within 30 days after 
discharge, as done in Study 2. This approach ensures a PPV of 90% for incident VTE 
diagnoses 120. This approach was not possible in Study 3 where the 30 days after 
discharge were used to classify the patients as initiators or non-initiators. Instead, 
in Study 3, we only included primary codes likely increasing the PPV 121. Of note, in 
the validation study when deriving at the PPV of 91% both primary and secondary 
codes were used 121.  
In Study 1, the exposure of interest was the incident VTE-type. The definition of 
‘provoked’ VTE was based on a review of international guidelines and relevant 
literature, in combination with available codes in the registries. More 
diseases/conditions could have been relevant to include in a ‘provoked’ VTE 
definition had they had an ICD-code. Consequently, there is a risk of 
misclassification of patients with ‘provoked’ VTE as ‘unprovoked’ patients. This 
misclassification is, however, most likely not related to the outcome making it non-
differential. In Study 1, we also defined a group consisting of patients with 
‘unprovoked’ VTE for whom the risk of occult cancer was not taken into account.  
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Recurrent VTE: Some recurrent VTE diagnoses in the registries may reflect 
subsequent examinations related to the incident VTE event rather than actual 
recurrent VTE. Clinically, it may be difficult to determine whether the finding of a 
DVT at a 3-month follow-up visit represent recurrent event or not. For recurrent 
VTE, a relevant imaging examination in association with a diagnosis ensures a PPV 
of 82%. This definition was used in both Study 1 and 2 (Table 9). Accordingly, 18% 
may be misclassified and falsely coded as suffering recurrence. These patients will, 
as opposed to the patients with a false incident VTE diagnosis, lead to an 
overestimate of the recurrence rate. The PPV of recurrent VTE is not validated for 
specific sub-types of patients, e.g. patients with cancer, patients with ‘unprovoked’ 
VTE, and patients with specific co-morbidities. However, the misclassification of 
recurrence is most likely not related to the exposure making it non-differential in 
relation to our exposure groups. In Study 1, we minimized the risk of repeated 
coding (inclusion of falsely coded recurrent events) further by starting follow-up 10 
days after discharge from the hospital. In both Study 1 and 2, the recurrent 
diagnoses were restricted to primary codes which we expect will increase the PPV 
further, although this was not specifically investigated in the validation study 121. 
Conversely, some factors contribute to underestimation as previously mentioned; 
not including emergency ward diagnoses, and fatal VTE’s never registered as VTE 
events. Hence, the ‘true’ magnitude of VTE recurrence is therefore impossible to 
perfectly estimate using administrative registries. 
In Study 3, the outcome was not redeeming a prescription within 30 days of 
discharge. This information was based on data from The Danish National 
Prescription Registry 123, containing individual-level information for all prescriptions 
claimed since 1994. The PPV of this outcome was therefore 100% with no 
misclassification issues. 
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Table 9: Diagnoses and Positive Predictive Values (PPV’s) by varying definitions 
Study 1 Study 2 Study 3 
Study 
population 
Incident VTE Incident VTE Incident VTE 
Study 
population 
requirements 
Imaging 
examination: 
PPV 91%. 
Initiating 
anticoagulation: 
PPV 90%. 
Imaging 
examination: PPV 
91% + primary 
diagnosis.  
Outcome Recurrent VTE. Recurrent VTE. Not initiating 
anticoagulation. 
Outcome 
requirements 
Imaging 
examination: PPV 
82% + primary 
diagnosis. 
Imaging 
examination: PPV 
82% + primary 
diagnosis. 
Not redeeming a 
prescription 
within 30 days of 
discharge: PPV 
100%. 
SELECTION ISSUES 
Another type of bias is selection bias. Selection bias can be introduced both at the 
time of study conception or during the study process 119. In the design phase of a 
study, selection bias can occur if there is a systematic difference between exposure 
and outcome in those included in the study compared with those not included, but 
otherwise eligible for the study. However, especially in register-based cohort 
studies, selection at entry into the cohorts is rarely associated with the outcome, 
since the outcome has not, or at least should not have, occurred at the time of 
enrolment. During the analytic phase of a study, selection bias can arise from 
censoring due to differential loss to follow-up or competing risk (informative 
censoring) 124. However, as the registers offer almost complete follow-up, the 
potential selection bias arising from informative censoring due to loss to follow-up 
was negligible. 
DEATH AS COMPETING RISK OR RECURRENT VTE 
As mentioned, selection bias can occur as a result of competing risk. A competing 
event is something that precludes or fundamentally alter the probability of the 
occurrence of the event of interest 90. When trying to determine the risk of 
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recurrent VTE, death can be thought of as a competing event. Translated to VTE 
research, this means that when a patient suffers a VTE and dies 5 months after the 
clinical event, estimating the risk of recurrence for this patient 2 years after 
incident VTE is not feasible. If mortality risk varies in sub-groups of a study, this 
might constitute a problem when using time-to-event analysis, where the 
assumption of non-informative censoring must not be violated. Focus on 
competing risk has recently emerged and few studies take this into account when 
considering VTE recurrence risk 33,39,125. However, when dealing with a potentially 
fatal outcome such as recurrent VTE, it may not be reasonable to categorise all 
deaths as competing events, since some fatal VTE events are likely to not have 
been coded as such. 
Another possibility is that death after incident VTE is a recurrent fatal VTE event. In 
that case the patient should not be censored in a time-to-event analysis but instead 
registered as suffering the outcome of recurrent VTE. Death associated with 
recurrent VTE was examined in a review from 2018 on 6,758 patients with a first 
‘unprovoked’ VTE. The authors found the rate of fatal recurrent VTE was 0.17 (95% 
CI 0.05–0.33) per 100 py one year after anticoagulation cessation 126. The review 
included 18 studies with varying definitions of fatal recurrent VTE. In a dated 
Danish study from 1989 investigating the presence of PE in autopsy material from a 
general population, 210 patients (13%) of a total of 1.603 patients had PE at 
autopsy. Of the 74 cases with lethal PE, two thirds were not recognized with PE 
prior to autopsy. The study concluded that the vital statistics of the Danish Board of 
Health underestimate the true number of cases and that PE should be considered 
in the differential diagnosis more frequently 127. The same conclusion was reached 
in a study from 1995: a PE diagnosis was unsuspected in 14 of 20 (70.0%; 95% CI 
45.7;88.1) patients who in autopsy were found to die from PE 128. This could argue 
that the risk of dying from recurrent VTE is in fact higher than estimated in studies 
not using autopsy data. 
In Study 1 and 2, we used time-to-event analysis treating death as a censoring 
event (not a recurrent VTE). In both studies, however, we used the Aalen-Johansen 
estimator, assuming death as competing risk, to depict the cumulative absolute 
recurrence risk. Furthermore, in Study 2, we did a supplementary analysis 
investigating the performance of the risk scores when predicting risk of recurrent 
VTE and death as a combined outcome. Using these analytic approaches, we 
investigated the performance of the models when all deaths were considered 
potential recurrent events instead of a competing event. In Study 3, patients dying 
75 
within the 30 days of discharge without redeeming a prescription were excluded. If 
anything, this exclusion will then lead to a possible underestimation of the 
proportion of non-initiators as defined by the 30-day mark since the group 
excluded were all non-initiators. 
GENERALISABILITY 
Generalisability or external validity is the degree to which the results of scientific 
findings hold true in other populations than the study population itself 119. As 
debated under “Validation of prediction models”, the predictors found in Study 2 
should be externally validated in other cohorts, before used in clinical practice. 
Furthermore, the results of Study 2 are based on VTE patients initiating and 
discontinuing anticoagulation within 1.5 years. In Study 3, the results were found 
after excluding non-initiators dying within 30 days after discharge. Finally, risk of 
recurrence investigated in Study 1, was based on patients hospitalized in Denmark 
with a VTE. These apparent choices does not mean that the results are biased but 
should instead be considered when evaluating for whom the results are valid and 
relevant for.  
EFFECT MODIFICATION BY ANTICOAGULATION 
When investigating recurrent VTE the risk estimates are likely to be modified by 
anticoagulation treatment. Effect modification occurs when the strength of the 
relationship between the primary exposure (incident VTE) and the outcome 
(recurrent VTE) differs depending on the level of a third variable (anticoagulation) 
119. Hence, anticoagulation may be considered an effect modifier by significantly
lowering recurrence risk and death in patients with VTE 129.
Unselected cohorts of patients with VTE not treated with anticoagulation no longer 
exist. Consequently, the natural history between incident VTE and recurrent VTE 
can no longer be studied using contemporary data, and researchers investigating 
recurrence risk are required to choose between different approaches. One option 
is to define a cohort using only patients not treated with anticoagulant agents, and 
subsequently censor patients once they initiate antithrombotic treatment. 
Importantly, this approach lacks of knowledge about why these particular patients 
were left untreated. This may impact on the generalizability of the results. Another 
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option is to include all patients with VTE irrespective of anticoagulant treatment 
status during follow-up, and describe an association recognizing that treatment 
status may vary. In Denmark, most cancer-free patients are treated for a time-
limited period of 3-6 months after incident VTE 19. Assuming that the treatment-
status primarily varies during the first year, in Study 1, the main analysis included 
all incident VTE patients. However, because of a continued indication for 
anticoagulation, we excluded patients with atrial fibrillation and patients with pre-
existing oral anticoagulant use within the last year. Furthermore, we conducted a 
supplementary analysis, repeating the main analysis with restriction of the study 
population to patients who had claimed a prescription for oral anticoagulation 
within 10 days of discharge from the index event. Results of the supplementary 
analysis restricted to patients on OAC treatment did not differ from results of the 
main analysis.  
In Study 2, we aimed to describe recurrence risk for an untreated population. The 
study population was followed from discontinuation of anticoagulation based on 
information from the Danish National Prescription Registry, 123. After start follow-
up, patients were censored if they resumed anticoagulation. Hence, we expect no 
effect modification by anticoagulation in this study.  In Study 3, we used the same 
registry to identify patients initiating treatment within 30 days after discharge as 
opposed to non-initiators not redeeming a prescription within this period. 
Anticoagulation was therefore not an effect modifier in that study, rather it was 
used to define the outcome (to not initiate anticoagulation). Since the prescription 
registry holds information on all claimed prescription drugs, the PPV of this 
outcome can be classified as 100%. That said, dispensing a prescription for a drug 
at the pharmacy is not equivalent to actually taking the drug as prescribed. 
CAUSALITY VERSUS PREDICTION 
Importantly, descriptive studies or studies of prediction should not be mistaken for 
aetiological studies 130. Aetiology aims at clarifying a causal effect of a specific 
exposure on an outcome. In non-randomised studies, this requires control for 
confounding factors selected based on pre-existing knowledge of causal relations 
131. Confounding as a concept is therefore a type of bias specific to studies on
causality. In contrast, prediction aims at accurately predicting the risk of an
outcome using multiple predictors collectively, regardless of whether the
predictors have a causal relationship with the outcome 130.
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In Study 2, our aim was to predict risk of recurrent VTE. The developed models are 
based on statistical associations that are not necessarily causal associations 
between the specific risk component and outcome. Although tempting, the AIM-
SHA-RP-variables cannot be interpreted with a causal meaning, e.g., that statin 
users carry a lower risk of VTE recurrence cannot be interpreted as statins per se 
prevent recurrent VTE – rather, statin use is an easily obtainable predictor or 
marker of lower risk of recurrent VTE. Furthermore, in Study 2 chronic renal 
disease was associated with a lower risk of recurrence. By intuition, a clinician will 
probably struggle to see the logic in that result. However, based on our study, the 
underlying reason for these associations cannot be understood. Some of the 
included components might be known as causes of (recurrent) VTE, but they are 
included in the models because they serve as easy obtainable patient 
characteristics that provide useful prognostic information in patients with VTE -not 
because they are known to cause VTE. 
In Study 1, we described the risk of recurrence according to incident VTE type, and 
in Study 3 we searched to clarify potential predictors of not initiating 
anticoagulation. None of these were studies of causality and confounding was 
therefore by definition not a specific concern 132. That said, whether specific 
information not available in the registries, e.g. lifestyle, would improve the 
prediction of anticoagulant non-initiation, remains unknown. 
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CONCLUSIONS AND PERSPECTIVES 
Anticoagulant VTE treatment is filled with dilemmas. Several issues require 
considerations before we can determine the optimal anticoagulant treatment for 
the many patients suffering from VTE.  
Risk of recurrence and bleeding 
Ideally, VTE risk stratification should help the decision of anticoagulant treatment 
duration by estimating a recurrence risk and identifying low or high-risk subgroups 
who should stop or continue treatment, respectively. Study 1 investigated the 
dilemma of recurrence risk according to the stratification used in most guidelines, 
namely: ‘provoked’/’unprovoked’/’cancer-related’ VTE. This was undertaken 
knowing that the concept ‘provoked VTE’ is not consistently defined making a 
unanimous categorization challenging. Recurrence was generally frequent affecting 
15-20% of all incident VTE patients after 10 years of follow-up. Patients with
‘cancer-related’ VTE had the highest recurrence risk followed by patients with
‘unprovoked’ VTE. However, an overall high recurrence risk in all types of VTE –
also after ‘provoked’ VTE – underscored that refinement is needed to optimize risk
stratification for VTE patients.
In Study 2, two new risk prediction scores under the joint acronym AIM-SHA-RP for 
men and women were developed. The models were designed to disregard the 
historical distinction of ‘unprovoked’ and ‘provoked’ incident VTE. After further 
external validation, these new risk scores may prove as useful shared decision-
making tools to guide the dilemma of duration of anticoagulation after incident VTE 
in everyday clinical practice.  
The risk of recurrence and consequent treatment duration should be balanced 
against an associated risk of bleeding while anticoagulated. For decades, VKA has 
been the only treatment option after VTE, but is now partly replaced by the NOACs. 
However, uncertainty remains in estimates of the long-term risk of major bleeding 
if treatment is continued. Furthermore, limited data exist on which is the safest and 
most effective NOAC due to lack of head-to-head trials comparing the NOACs 58,63. 
The newly developed reversal agents for the NOACs may support the paradigm 
shift towards extended treatment duration.  
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Adherence and patient preference 
Despite of the NOACs offering practical advances for the patient compared to VKA, 
many patients with VTE never initiate relevant anticoagulant treatment. Study 3 
identified that up to 24% did not initiate anticoagulant treatment 30 days after 
discharge with an incident VTE event. Improving information or treatment follow-
up strategies for patients with specific characteristics may improve treatment 
patterns. However, the many facets of medication adherence precludes an easy 
accessible strategy for treatment optimization. Future targeted optimized 
adherence interventions have to consider both a clinical and academic perspective 
to reach the goal of improved treatment for patients suffering a VTE. However, 
facilitating this requires patient-tailored interventions and health professionals 
need to better understand adherence, besides offering anticoagulation to 
appropriate patients. Whether the effort should focus on generally reducing the 
total proportion of untreated, or if actions should be targeted few specific patients, 
with high risk of not being treated, remains undetermined.  
Register-based VTE research 
The Danish national healthcare system provides a unique setting for conducting 
large population-based studies of VTE. The civil registration number makes it 
possible to link medical databases and administrative registries, and thereby 
construct large cohorts with detailed longitudinal data that include comorbidity 
data from hospital contact history, and complete long-term follow-up data. Our 
studies have, however, also encountered some of the weaknesses in the Danish 
health care databases. The coding of VTE diagnoses is not rigorous as seen in, 
especially, moderate PPV for VTE recurrence codes. Also, there is a lack of relevant 
VTE codes in the registries including distal/proximal position of a DVT. An ideal 
future prediction model for VTE recurrence could be using big data and machine 
learning techniques implementing both electronic medical records, socio-economic 
data, geographic factors and allow for a much more detailed characterization of 
patients and thereby precise risk estimate of both recurrence and bleeding risk. 
In conclusion, this Ph.D. dissertation emphasizes that there is a continued need for 
improvement of VTE treatment and management. It clarifies that VTE recurrence is 
common after all types of VTE, and that many patients receive no or potentially 
sub-optimal anticoagulant treatment. The concept of VTE is undergoing a major 
transition in the scientific and clinical community as we increasingly consider VTE 
as a chronic illness. The presented studies may help navigate some of the VTE 
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dilemmas and together with other scientific contributions support the decision of 
anticoagulant treatment duration of the many patients with VTE.  
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